Xilio Therapeutics (XLO) Operating Leases (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Operating Leases data on file, last reported at $5.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 20.85% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 20.85% YoY), and the FY2025 full-year result was $5.6 million, down 19.31% from the prior year.
• Operating Leases fell to $5.3 million in Q1 2026, from $5.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.9 million in Q1 2022 to a low of $5.3 million in Q1 2026.
• A 5-year average of $7.8 million and a median of $7.9 million in 2024 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases slipped 8.6% in 2022 and retreated 20.85% in 2026, its largest moves.
• Tracing XLO's Operating Leases over 5 years: stood at $9.2 million in 2022, then declined by 11.39% to $8.1 million in 2023, then decreased by 14.59% to $7.0 million in 2024, then dropped by 19.31% to $5.6 million in 2025, then decreased by 6.36% to $5.3 million in 2026.
• Business Quant data shows XLO's Operating Leases at $5.3 million in Q1 2026, $5.6 million in Q4 2025, and $6.0 million in Q3 2025.